ArticleIranian journal of biotechnology2026
Rapid Detection of Carbapenemase-Producing Acinetobacter Baumannii Using MALDI-TOF Mass Spectrometry: A Technological Advancement in Clinical Microbiology.
Article in Iranian journal of biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The emergence of CRAB presents a critical challenge in healthcare settings, necessitating rapid and accurate detection methods. MALDI-TOF MS has emerged as a promising technology for antimicrobial resistance detection, offering advantages over conventional molecular assays. Objective: This study evaluates the diagnostic performance and clinical applicability of MALDI-TOF MS for the rapid identification of carbapenemase-producing A. baumannii isolates, aiming to enhance laboratory efficiency and antimicrobial stewardship. Materials and Methods: A total of 200 clinical A. baumannii isolates were collected from a tertiary care hospital in China throughout 2023. Carbapenemase activity was assessed using MALDI-TOF MS, and results were compared against molecular identification of carbapenemase-encoding genes via multiplex PCR. Diagnostic performance metrics, including sensitivity, specificity, and predictive values, were analyzed. Results: MALDI-TOF MS demonstrated high diagnostic accuracy, correctly identifying carbapenemase activity in 95 of 100 CRAB isolates and classifying 98 of 100 carbapenem-susceptible strains. Molecular assays confirmed the presence of carbapenemase genes in 96 resistant isolates. Performance metrics showed MALDI-TOF MS achieved a sensitivity of 98.96%, specificity of 99.00%, and overall accuracy of 98.98%. The system effectively detected various carbapenemase types, including OXA-48-like enzymes (40%), New Delhi metallo-β-lactamase (30%), Klebsiella pneumoniae carbapenemase (15%), Verona integron-encoded metallo-β-lactamase (10%), and active-on-imipenem (IMP) (1%), with a single missed detection of an IMP-producing isolate. Conclusion: MALDI-TOF MS offers a rapid, reliable, and cost-effective approach for carbapenemase detection in A. baumannii, significantly improving the speed of antimicrobial resistance screening in clinical laboratories. Its seamless integration into existing workflows enhances diagnostic efficiency and supports real-time antimicrobial resistance surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.